Last reviewed · How we verify

DAPT, Statin

Samsung Medical Center · Phase 2 active Small molecule

DAPT inhibits platelet aggregation by blocking the P2Y12 receptor.

DAPT inhibits platelet aggregation by blocking the P2Y12 receptor. Used for Acute coronary syndrome, Myocardial infarction, Ischemic stroke.

At a glance

Generic nameDAPT, Statin
Also known asDES, BMS
SponsorSamsung Medical Center
Drug classAntiplatelet
TargetP2Y12 receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Mechanism of action

DAPT works by selectively and reversibly inhibiting the P2Y12 receptor on platelet surfaces, which prevents adenosine diphosphate (ADP) from binding and activating platelets. This action reduces platelet aggregation and subsequent thrombus formation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: